INNATE PHARMA SP.ADR/1 (IDDA) - Total Liabilities
Based on the latest financial reports, INNATE PHARMA SP.ADR/1 (IDDA) has total liabilities worth €84.42 Million EUR (≈ $98.70 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore INNATE PHARMA SP.ADR/1 (IDDA) equity growth momentum to track the company's year-over-year net asset growth rate.
INNATE PHARMA SP.ADR/1 - Total Liabilities Trend (2021–2025)
This chart illustrates how INNATE PHARMA SP.ADR/1's total liabilities have evolved over time, based on quarterly financial data.
INNATE PHARMA SP.ADR/1 Competitors by Total Liabilities
The table below lists competitors of INNATE PHARMA SP.ADR/1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Apiam Animal Health Ltd
AU:AHX
|
Australia | AU$134.72 Million |
|
Kalray SA
PA:ALKAL
|
France | €23.73 Million |
|
e-Credible Co. Ltd
KQ:092130
|
Korea | ₩22.81 Billion |
|
Gabelli Global Utility & Income Tr
NYSE MKT:GLU
|
USA | $291.78K |
|
Leap Therapeutics Inc
NASDAQ:LPTX
|
USA | $8.70 Million |
|
KOMPLETT ASA NK -40
F:GJ60
|
Germany | €4.46 Billion |
|
X Financial Class A
NYSE:XYF
|
USA | $6.76 Billion |
|
SaraminHR Co.Ltd
KQ:143240
|
Korea | ₩40.83 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down INNATE PHARMA SP.ADR/1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of INNATE PHARMA SP.ADR/1.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.89 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how INNATE PHARMA SP.ADR/1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for INNATE PHARMA SP.ADR/1 (2021–2025)
The table below shows the annual total liabilities of INNATE PHARMA SP.ADR/1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €84.42 Million ≈ $98.70 Million |
-17.41% |
| 2024-12-31 | €102.22 Million ≈ $119.51 Million |
-17.08% |
| 2023-12-31 | €123.29 Million ≈ $144.13 Million |
-15.06% |
| 2022-12-31 | €145.14 Million ≈ $169.69 Million |
-9.32% |
| 2021-12-31 | €160.06 Million ≈ $187.12 Million |
-- |
About INNATE PHARMA SP.ADR/1
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Mo… Read more